Janus Henderson Group
NRIX icon

Janus Henderson Group’s Nurix Therapeutics NRIX Stock Holding History

Janus Henderson Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$610K Hold
39,400
– – ﹤0.01% 1921
2025
Q4 		$748K Buy
39,400
+13,200
+50% +$190K ﹤0.01% 1824
2025
Q3 		$242K Hold
26,200
– – ﹤0.01% 2285
2025
Q2 		$298K Hold
26,200
– – ﹤0.01% 2172
2025
Q1 		$318K Hold
26,200
– – ﹤0.01% 2182
2024
Q4 		$494K Hold
26,200
– – ﹤0.01% 2041
2024
Q3 		$588K Hold
26,200
– – ﹤0.01% 1954
2024
Q2 		$547K Buy
+26,200
New +$408K ﹤0.01% 1946
2023
Q4 		– Sell
-12,933
Closed -$102K – 2588
2023
Q3 		$102K Buy
12,933
+10
+0.1% +$91 ﹤0.01% 2514
2023
Q2 		$129K Sell
12,923
-31
-0.2% -$316 ﹤0.01% 2542
2023
Q1 		$115K Buy
+12,954
New +$135K ﹤0.01% 2605

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Janus Henderson Group's NRIX Position: Q1 2026 in Review

Janus Henderson Group held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 39,400 shares worth $610K. The position accounts for ﹤0.01% of the portfolio, ranked #1921.

Janus Henderson Group first reported a position in NRIX in Q1 2023 and has held it in 11 quarters since. The position peaked at $748K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Janus Henderson Group held 39,400 shares of Nurix Therapeutics worth $610K as of Q1 2026.
  • Janus Henderson Group left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1921 holding.
  • Janus Henderson Group first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 11 quarters since.
  • Janus Henderson Group's Nurix Therapeutics position peaked at $748K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.